GLPBio

H-Lys-OH·HCl

Catalog No.: GA10718Purity:>98.00%

製品は研究用途にのみ使用できます。人体には使用できません。患者への販売は行っておりません。


H-Lys-OH·HCl
Cas No.: 657-27-2
500gQuote
Contact for Price

引用文献 (Citations)

現在、この製品の引用文献はありません。以下はGlpBio製品を引用した代表的な文献です。
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

製品説明 (Description)

L-lysine hydrochloride is an essential amino acid for humans with various benefits including treating herpes, increasing calcium absorption, reducing diabetes-related illnesses and improving gut health.

L-lysine treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhances antioxidant activity. Pre- or post-treatment with L-lysine leads to significant decreases in the levels of malondialdehyde and nitric oxide, while significant enhancement is observed in the activities of antioxidant enzymes (superoxide dismutase, catalase, and glutathione peroxidase) and glutathione[1]. L-lysine supplementation almost completely ameliorates vascular calcification. Dietary L-lysine strongly suppresses plasma intact parathyroid hormone in adenine rats and supports a proper bone-vascular axis. The conserved orientation of the femoral apatite in group Lys also evidences the bone-protective effects of L-lysine. Dietary L-lysine elevates plasma alanine, proline, arginine, and homoarginine but not lysine[2]. The dose-dependent delay in gastric emptying observed in rats is confirmed in humans with an increase in halftime of gastric emptying of 4 min/g L-lysine. Moreover, a dose-dependent increase in intestinal fluid accumulation is observed (0.4 mL/min/g L-lysine)[3].

References:
[1]. Al-Malki AL, et al. Suppression of acute pancreatitis by L-lysinein mice. BMC Complement Altern Med. 2015 Jun 23;15:193.
[2]. Shimomura A, et al. Dietary L-lysineprevents arterial calcification in adenine-induced uremic rats. J Am Soc Nephrol. 2014 Sep;25(9):1954-65.
[3]. Baruffol C, et al. L-lysine dose dependently delays gastric emptying and increases intestinal fluid volume in humans and rats. Neurogastroenterol Motil. 2014 Jul;26(7):999-1009.

実験プロトコル (Protocol)

Animal experiment:

Rats: Nephrocalcinosis in 6-week-old male Wistar rats is induced by continuous injection of rat PTH 1-34 at a dosage of 40 μg/kg per day via an osmotic mini-pump for 50 hours. L-lysine HCl or glycine at a dose of 20 mmol/kg is administered via a gastric tube at 2 hours, 14 hours, 26 hours, and 38 hours after the implantation of the osmotic pump. At the indicated periods, Serum and urinary biochemical parameters, urea nitrogen, albumin, calcium, inorganic phosphate, and magnesium are determined by clinical diagnostic reagents[2]. Mice: Four groups of mice (10 in each group) are assessed. Group I is the control. Animals in groups II-IV are injected intraperitoneally with L-arginine hydrochloride (400 mg/kg body weight [bw]) for 3 days. Group III animals are orally pre-treated with L-lysine(10 mg/kg bw), whereas group IV animals are orally post-treated with L-lysine(10 mg/kg bw). Serum samples are subjected to amylase, lipase, transaminase, and interleukin-6 (IL-6) assays. The pancreas is excised to measure the levels of malondialdehyde, nitric oxide, catalase, superoxide dismutase, reduced glutathione, and glutathione peroxidase[1].

References:

[1]. Al-Malki AL, et al. Suppression of acute pancreatitis by L-lysinein mice. BMC Complement Altern Med. 2015 Jun 23;15:193.
[2]. Shimomura A, et al. Dietary L-lysineprevents arterial calcification in adenine-induced uremic rats. J Am Soc Nephrol. 2014 Sep;25(9):1954-65.
[3]. Baruffol C, et al. L-lysine dose dependently delays gastric emptying and increases intestinal fluid volume in humans and rats. Neurogastroenterol Motil. 2014 Jul;26(7):999-1009.

製品資料 (Product Documents)

Purity:>98.00%Appearance:A solid

化学的性質 (Chemical Properties)

CAS番号
657-27-2
化学名
(2S)-2,6-diaminohexanoic acid;hydrochloride
SMILES
C(CCN)CC(C(=O)O)N.Cl
分子式
C6H14N2O2.HCl
分子量
182.7
溶解性
Water : 100mg/mL
保存条件
Store at 2-8°C
一般的な注意事項
製品の溶解性データに基づいて適切な溶媒を選択してください。調製後は、凍結融解の繰り返しを避けるため、ストック溶液を小分けしてください。
ストック溶液は、-80°Cで保存する場合は6か月以内、-20°Cで保存する場合は1か月以内に使用してください。
溶解性を高めるには、チューブを37°Cに温め、適切な時間超音波処理してください。
配送条件
評価用サンプルは保冷剤とともに発送します。その他の容量は室温で発送し、ご要望に応じて保冷剤を同梱します。

計算ツール (Calculators)モル濃度 / 希釈 / 分子量 / 単位変換 / in vivo製剤 / 溶解度

g/mol

Reviews

Review for H-Lys-OH·HCl

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%